Navigation Links
Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Date:1/25/2013

DEERFIELD, Ill. and OSAKA, Japan, Jan. 25, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

"Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience," said Douglas Cole , president, Takeda Pharmaceuticals U.S.A., Inc. "Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population."

NESINA is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). OSENI, which combines alogliptin with pioglitazone, is the first product in the U.S. to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. KAZANO combines alogliptin with metformin HCl, a widely used anti-diabetes medication, in a single tablet.

The most common adverse events (greater than or equal to 4%) reported with NESINA include nasopharyngitis, headache and upper respiratory tract infection. With regard to OSENI, common adverse events (greater than or equal to 4%) reported include nasopharyngitis, back pain and upper respiratory tract infection. Common adverse events (greater than or equal to 4%) re
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
2. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
3. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
4. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
5. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
6. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
7. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
8. Zimmer Receives FDA Clearance for Revolutionary New Surgical Guidance Technology
9. American Capital Receives $60 Million From The Sale Of Lifoam Holdings And Generates An 11% Return On Its Investment
10. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
11. Brolex C SAFE cesarean section safety device receives top scores, rated a MUST HAVE medical device for performing c/sections.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , June 26, 2015 Research ... "Vitamin D Market by Analog, Application, End-User & by ... to their offering. This market is projected to ... vitamin D in different applications and rising opportunities in countries ... , Italy , and ...
(Date:7/2/2015)... July 2, 2015   EVO Aesthetic Center and ... provider for non-invasive aesthetics in Lakeway, Texas ... treatments with the Astanza Duality laser. The medical spa ... through various medical and laser procedures. Their addition of ... a clear solution to their tattoo regret. ...
(Date:7/2/2015)... 2015 Numotion,s Board of Directors and ... Tamas Feitel has joined the Company as Chief ... highly successful 18 year career at GE serving in ... and productivity to result in significant industry leading growth ... Financial Officer for GE Healthcare Global Services, a $5B ...
Breaking Medicine Technology:Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Numotion Names Tamas Feitel Chief Financial Officer 2
... Timothy Mastro,MD, FACP, DTM&H, who joins Family Health ... Research, will share information on promising,research into pre-exposure ... Conference in Mexico City., Dr. Mastro,s presentation, ... ongoing and upcoming clinical trials that,suggest oral doses ...
... Key Thought,Leaders Explore Critical Next Steps for AIDS Vaccine ... NEW YORK, July 28 The following was ... Today, AIDS vaccine research is at a pivotal ... to reach late-stage testing failed.,In the wake of this ...
Cached Medicine Technology:HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2AIDS Vaccines: Where Do We Go From Here? 2
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... With summer in full swing, Americans are ... is one of the top spots for fishing in the world, and it’s easy to ... of Ontario, Canada has great fish. , Recreational fishing is a huge industry, and ...
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... the most versatile smart light bulbs on the market. , According to the U.S. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first introduced, they have ... Their significant popularity has inspired four new, fun shades including: blue, lime, pink ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Six months ahead ... solo cross-country walk to raise awareness and money for the Pulmonary Hypertension Association ... arrive at PHA’s headquarters near Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday ...
(Date:7/2/2015)... ... July 02, 2015 , ... ActiveBunch.com recently launched as a social network ... to function as a lifestyle community, Active Bunch allows users to connect with like-minded ... and participate in discussions or group events. , The spokesperson for Active Bunch ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... ... accepted CoolTouch,s request to re-examine the ,873 Paolini laser lipolysis patent based on prior art ... ... the United States Patent & Trademark Office (USPTO) accepted CoolTouch,s request to re-examine the ,873 ...
... ... Hepatitis C and their physicians, caregivers and families, has been redesigned. New features include ... ... The go-to website that provides a wealth of information and news updates about ...
... 2 The University HealthSystem Consortium (UHC) today announced ... added to Spend LINK (TM), UHC,s proprietary supply chain ... optimize their pricing and achieve maximum savings. , ... hospital,s expenditure, making it the second largest expense after ...
... at Westmead are embarking on a ground-breaking new study ... resistance in overweight adolescents can put the brakes on ... diabetes affects 85 to 90 per cent of all ... younger people and children are increasingly being diagnosed. Often ...
... for ,Loose Chains, joins researchers, physicians, neurosurgeons and other brain tumor ... Medical Center , , LOS ... have to work around scheduling conflicts, but Eddie Cleland, drummer for ... to accommodate brain tumor surgery, which was performed by ...
... well known to stop or suppress cancer plays a role in ... of Michigan Comprehensive Cancer Center. The researchers found that several pathways ... breast cancer stem cells. Further, by using a drug that ... percent decrease in the number of cancer stem cells within a ...
Cached Medicine News:Health News:United States Patent and Trademark Office Accepts CoolTouch's Re-examination Request for Cynosure '873 Patent 2Health News:Resource for Those Living with Hepatitis C Announces Website Redesign 2Health News:University HealthSystem Consortium Adds Price Competitive Index to Its Spend Analytics Tool 2Health News:Ground-breaking study to cap the growing trend of type 2 diabetes in overweight adolescents 2Health News:Drummer Eddie Cleland Resumes Life After Brain Surgery and Tells About it at Conference 2Health News:Drummer Eddie Cleland Resumes Life After Brain Surgery and Tells About it at Conference 3Health News:Drummer Eddie Cleland Resumes Life After Brain Surgery and Tells About it at Conference 4Health News:U-M researchers link pathway to breast cancer stem cells 2
West 2 periosteal elevators....
Alexander periosteal elevators....
Sedillot periosteal elevators....
Modified Freer periosteal elevator, #163, slight curve, 21 cm....
Medicine Products: